Public Advisory - Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
OTTAWA, ON, Aug. 20, 2022 /CNW/ -
Summary
Product: pms-Hydromorphone, 2 mg tablets (DIN 00885436) marketed by Pharmascience Inc. Sold to pharmacies in bottles of 100 tablets for dispensing to consumers.
Issue: Health product ? product safety
What to do: Check your bottle of pms-Hydromorphone to ensure you have the correct tablets. Stop using product from the affected lot and contact your pharmacy immediately for a replacement product.
Who this is for: General public and pharmacists
Product Image(s):
2 mg: Round, biconvex, orange tablet debossed and half-scored with "2"on one side of the tablet and "pms" on the other side.
8 mg: Round, biconvex, white tablet debossed and half-scored with "8"on one side of the tablet and "pms" on the other side.
Affected products
Product
DIN
Lot
Expiry date
Pharmascience Inc. pms-Hydromorphone 2 mg Hydromorphone Hydrochloride Tablets
Bottles of 100 tablets
00885436
639268
31-01-2026
Issue
Pharmascience Inc. is recalling one lot of pms-Hydromorphone, 2 mg tablets, (lot 639268) as the bottles may contain hydromorphone tablets of a different strength (8 mg), meaning they contain higher amounts of hydromorphone. Products from the affected lot were sold between May 2022 and August 2022.
The 2 mg hydromorphone tablets are round and orange with a "2" on one side of the tablet and "pms" on the other side. The 8 mg hydromorphone tablets are round and white with an "8" on one side of the tablet and "pms" on the other side.
Hydromorphone is an opioid medication used to treat pain and opioid use disorder.
Accidentally taking too much hydromorphone (one dose of 8 mg of hydromorphone instead of one dose of 2 mg) or suddenly increasing the dose of hydromorphone could potentially lead to an overdose, which can be life-threatening even in people who have some tolerance to opioids.
Symptoms of hydromorphone overdose may include: dizziness, drowsiness, confusion, slow heartbeat, slow and difficult breathing, cold and clammy skin, seizure, coma and death.
Patients and their caregivers should be aware of the signs and symptoms of hydromorphone overdose, and should seek medical attention immediately if any of these symptoms are noted. If naloxone is available, be prepared to administer it.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
What you should do
Check your bottle of pms-Hydromorphone to ensure you have the correct tablets. The 2 mg hydromorphone tablets are round and orange with a "2" on one side of the tablet and "pms" on the other side. The 8 mg hydromorphone tablets are round and white with an "8" on one side of the tablet and "pms" on the other side.
Stop using product from the affected lot and contact your pharmacy immediately for a replacement product.
If you have accidentally taken the 8 mg hydromorphone tablet instead of the 2 mg hydromorphone tablet and you have any health concerns, or are unsure whether you have taken too much hydromorphone, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms. If naloxone is available, be prepared to administer it.
If you have any questions about the recall, contact Pharmascience Inc. at [email protected] or 1-888-550-6060.
Alert / recall type: Public Advisory Category: Drugs Companies: If you have any questions about the recall, contact Pharmascience Inc. at [email protected] or 1-888-550-6060. Published by: Health Canada
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...
WellSync, an API-driven virtual care service provider, today announced its partnership with The Vitamin Shoppe to launch Whole Health Rx, a cutting-edge telehealth service providing access to GLP-1 medications for weight management. WellSync provides...
May 17, 2024 Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI models applied to ECG digital biomarkers can help to improve diagnosis, reduce readmissions, and lower costs Amsterdam, the Netherlands...